Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.

被引：0
|
作者：
Kim, Sunnie S.
Signorovitch, James
Yang, Hongbo
Patterson-Lomba, Oscar
Xiang, Cheryl
Ung, Brian
Parisi, Monika
Marshall, John
机构：
[1] Georgetown Univ, Washington, DC USA
[2] Anal Grp Inc, Boston, MA USA
[3] Celgene Corp, Summit, NJ USA
[4] Georgetown Univ, Med Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [42] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
    Ingram, Myles A.
    Lauren, Brianna N.
    Pumpalova, Yoanna
    Park, Jiheum
    Lim, Francesca
    Bates, Susan E.
    Kastrinos, Fay
    Manji, Gulam A.
    Kong, Chung Yin
    Hur, Chin
    CANCER REPORTS, 2022, 5 (09)
  • [44] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States.
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric Andrew
    Fisch, Michael Jordan
    Aran, Dvir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16271 - E16271
  • [46] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [47] Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
    Williet, Nicolas
    Saint, Angelique
    Pointet, Anne-Laure
    Tougeron, David
    Pernot, Simon
    Pozet, Astrid
    Bechade, Dominique
    Trouilloud, Isabelle
    Lourenco, Nelson
    Hautefeuille, Vincent
    Locher, Christophe
    Desrame, Jerome
    Artru, Pascal
    Bidault, Anne Thirot
    Le Roy, Bertrand
    Pezet, Denis
    Phelip, Jean-Marc
    Taieb, Julien
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [48] Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
    Sawada, Masashi
    Kasuga, Akiyoshi
    Mie, Takafumi
    Furukawa, Takaaki
    Taniguchi, Takanobu
    Fukuda, Koshiro
    Yamada, Yuto
    Takeda, Tsuyoshi
    Kanata, Ryo
    Matsuyama, Masato
    Sasaki, Takashi
    Ozaka, Masato
    Sasahira, Naoki
    BMC CANCER, 2020, 20 (01)
  • [49] Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
    Masashi Sawada
    Akiyoshi Kasuga
    Takafumi Mie
    Takaaki Furukawa
    Takanobu Taniguchi
    Koshiro Fukuda
    Yuto Yamada
    Tsuyoshi Takeda
    Ryo Kanata
    Masato Matsuyama
    Takashi Sasaki
    Masato Ozaka
    Naoki Sasahira
    BMC Cancer, 20
  • [50] Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
    Williet, Nicolas
    Petrillo, Angelica
    Roth, Gael
    Ghidini, Michele
    Petrova, Mila
    Forestier, Julien
    Lopez, Anthony
    Thoor, Audrey
    Weislinger, Lucie
    De Vita, Ferdinando
    Taieb, Julien
    Phelip, Jean Marc
    CANCERS, 2021, 13 (11)
12345